

AMENDMENTS TO THE CLAIMS

1. – 2. (Canceled)

3. (Currently amended) A method for administering cyclosporin into cerebrospinal fluid or cerebrospinal fluid spaces of a patient, which comprises:

— providing a sterile injectable solution of cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and

— administering said cyclosporin and DMSO sterile injectable solution by injection into the a cerebrospinal fluid or cerebrospinal fluid spaces of said patient,

— wherein the concentration of cyclosporin is from 0.1% to 20% by weight of the total composition, and wherein DMSO is present in at least 80% by weight of the total composition.

~~wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.~~

4. (Currently Amended) A method for administering a sterile injectable solution of cyclosporin to a patient, which ~~comprises~~comprises:

— providing a sterile injectable solution of cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and

— administering said sterile injectable solution of cyclosporin and DMSO to said patient by intravestibular injection, into or adjacent to the brain, or into or adjacent to the spinal cord of said patient,

— wherein the concentration of cyclosporin is from 0.1% to 20% by weight of the total composition, and wherein DMSO is present in at least 80% by weight of the total composition.

~~wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.~~

5. **(Currently Amended)** A method for administering cyclosporin by injection ~~including—via intravenous,—intra-arterial—~~or ~~intraparenchymal—~~injection,—into a patient, which ~~comprises~~comprises:

- ~~— providing a sterile injectable solution of cyclosporin dissolved in DMSO according to claim 4 in a pharmaceutically acceptable carrier, and~~
- ~~— administering said sterile injectable solution of cyclosporin and DMSO by injection into an intravenous, intra-arterial or intraparenchymal spaces of said patient,~~
wherein the concentration of cyclosporin is from 0.1% to 20% by weight of the total composition, and wherein DMSO is present at least 80% by weight in the composition.

6. **(Currently Amended)** A method for administering cyclosporin inhalationally or nasally to a patient, which ~~comprises~~comprises:

- ~~— providing the cyclosporin dissolved in DMSO according to claim 4 in a pharmaceutically acceptable—solution carrier, and~~
- ~~— administering said cyclosporin and DMSO solution inhalationally or nasally to said patient,~~
wherein the concentration of cyclosporin is from 0.1% to 20% by weight of the total composition, and wherein DMSO is present at least 80% by weight in the composition.

7. **(Currently Amended)** The method of claim 3, 4, 5 or 6, wherein the cyclosporin is cyclosporin A or a salt thereof.

8. – 9. **(Canceled)**

10. **(Currently amended)** The method according to claim 3 wherein the administration of a sterile injectable solution of cyclosporin into said cerebrospinal fluid spaces—space is intraventricular or intrathecal.

11. **(Currently Amended)** A method for treating Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, HIV neuropathy, Guillain-Barré syndrome, neural transplantation, neural xenotransplantation, stroke, brain hemorrhage, brain and spine trauma, ionizing radiation, neurotoxicity of vestibular structures, or retinal detachment, which comprises: administering a sterile injectable solution of cyclosporin dissolved in DMSO

according to the method of claim 43, 4, 5 or 6 in a pharmaceutically acceptable carrier to said patient.

12. **(Currently Amended)** A method for inducing systemic immunosuppression in a patient of transplantation or autoimmune disease, which comprises: administering a sterile injectable solution of cyclosporin and DMSO according to the method of claim 3, 4, 5 or 6 to said patient.

13. - 20. **(Canceled)**

21. **(Currently amended)** The method according to claim 3, wherein the sterile injectable solution of cyclosporin dissolved in DMSO comprises a cyclosporin dissolved in dimethylsulfoxide (DMSO), wherein the concentration of cyclosporin is from 0.1% to 20% by weight of the total composition, and wherein DMSO is present in at least 80% by weight in of the total composition.

22. - 23. **(Canceled)**

24. **(Currently amended)** The method of claim 3, 4, 5 or 6 wherein a dose of from 50 to 450 mg/ 0.0001 to 200 mg/kg/day of cyclosporin is administered.

25. **(Currently amended)** The method of claim 3, 4, 5 or 6, wherein a dose of from 50 to 450 5 to 5000 mg/day of cyclosporin is administered.

26. **(Canceled)**